The quest to optimize long-term outcomes for patients undergoing transcatheter aortic valve replacement (TAVR) has reached a critical juncture. For years, the interventional cardiology community has debated whether the routine use of direct oral anticoagulants (DOACs) could mitigate the risks of subclinical leaflet thrombosis—a phenomenon observed via imaging as hypoattenuated leaflet thickening (HALT)—and whether such interventions translate into tangible clinical benefits.
Two major trials presented at the European Society of Cardiology (ESC) Congress in Munich have provided the most rigorous data to date, yet the consensus remains firmly anchored in current clinical practice: for patients without an independent indication for anticoagulation, single antiplatelet therapy (SAPT) remains the gold standard.
The ACASA-TAVI and NOTION-4 Data: A Tale of Two Trials
The ACASA-TAVI trial, a prospective, open-label, randomized study conducted across three high-volume Norwegian centers, sought to determine if DOAC monotherapy could effectively reduce the incidence of HALT compared to standard antiplatelet regimens.
The results, published simultaneously in JAMA, demonstrated that among 360 patients aged 65–80, those randomized to DOAC monotherapy experienced a 16.2% incidence of HALT at 12 months, compared to 28.6% in the antiplatelet group (RR 0.55; 95% CI 0.37-0.82; P=0.004). While this statistically significant reduction in imaging-based thrombosis was noteworthy, lead investigator Øyvind Lie, MD, PhD, MSc, of Oslo University Hospital, urged caution in interpreting these findings as a catalyst for immediate practice change.
In tandem, the NOTION-4 trial—published in the Journal of the American College of Cardiology—offered a sobering perspective. Involving 352 participants, this study compared lifelong SAPT to a 3-month course of upfront DOAC therapy followed by SAPT. While the short-term DOAC regimen showed a temporary reduction in HALT during the active treatment phase, this benefit evaporated within nine months of transitioning to antiplatelet therapy. Furthermore, the clinical safety data favored the SAPT group; the combined risk of all-cause mortality, stroke, or major/life-threatening bleeding was 2.3% for the SAPT cohort versus 8.2% for the short-term DOAC group.
Chronology of the TAVR Antithrombotic Debate
To understand the weight of these findings, one must look at the historical progression of antithrombotic strategies following TAVR:
- The Early Era: Initially, dual antiplatelet therapy (DAPT) was the default post-procedural strategy, borrowed from coronary stenting protocols. However, studies increasingly suggested that the bleeding risks associated with DAPT outweighed the ischemic benefits in the TAVR population.
- The Rise of HALT: With the advent of sophisticated cardiac CT imaging, clinicians began identifying HALT—a silent, subclinical thickening of the valve leaflets. The immediate clinical fear was that this represented the precursor to early valve degeneration and future thromboembolic events.
- The GALILEO and ATLANTIS Setbacks: Several large-scale, high-profile trials attempted to prove that DOACs (such as rivaroxaban) could provide a superior profile to antiplatelets. Instead, these trials revealed no clear benefit and, in some cases, suggested increased harm or mortality associated with potent anticoagulation in patients who did not require it for atrial fibrillation or other conditions.
- The ESC/ACC Guideline Shift: Based on the failures of earlier trials and the lack of robust evidence linking HALT to long-term clinical decline, clinical guidelines were updated to strongly discourage the routine use of anticoagulation post-TAVR in patients without an established indication.
- The Current Evidence (2026): With the presentation of ACASA-TAVI and NOTION-4, the medical community has essentially closed the door on the "routine DOAC" hypothesis, confirming that while DOACs can alter imaging signatures, they do not reliably improve hard clinical endpoints.
Supporting Data: Dissecting the Outcomes
The ACASA-TAVI study provided a detailed look at the mechanisms of TAVR post-procedural care. The participants, with a mean age of 74.5, were randomized to either DOACs—specifically apixaban (51%), edoxaban (41%), or rivaroxaban (8%)—or the default control of aspirin (75 mg).
While the DOAC group showed a numerical advantage in the reduction of leaflet involvement, the safety analysis—which tracked combined VARC-3 bleeding events, thromboembolic events, and all-cause mortality—revealed a 7.5% event rate in the DOAC group versus 10.6% in the antiplatelet group. Although this reached non-inferiority, the researchers emphasized that the trial’s lower-than-expected event numbers limit its definitive power.
The NOTION-4 data, conversely, highlighted the risks of "over-treating" patients. The significantly higher incidence of bleeding and mortality in the short-term DOAC group (8.2% vs 2.3%) serves as a potent reminder that every pharmacological intervention carries a non-negligible risk, especially in an aging, often frail, TAVR population.
Official Responses and Expert Consensus
The reaction from the broader interventional cardiology community has been one of confirmation rather than surprise. Stephan Windecker, MD, of Bern University Hospital, served as the formal discussant at the ESC Congress. His assessment was blunt: the DOAC-TAVR literature remains "overall non-conclusive."
"DOACs effectively reduce HALT, but the effect is not durable," Dr. Windecker noted. "It has not been conclusively shown to improve clinical outcomes, and routine screening for HALT is not recommended."
Dr. Windecker’s conclusion echoes the sentiment of current guidelines: "I would say that single antiplatelet therapy remains the default strategy. We need to shift our focus away from aggressive pharmacological management and instead pay attention to optimizing the actual TAVR implantation technique to inherently reduce the risk of HALT."
The study authors themselves have been transparent about the limitations of their work. Dr. Lie acknowledged that the ACASA-TAVI population was relatively young and low-risk compared to the broader, often much older, global TAVR patient demographic. Furthermore, the open-label nature of the trial, combined with a significant number of treatment deviations and crossovers, complicates the interpretation of the real-world utility of these findings.
Implications for Clinical Practice
For the practicing cardiologist, the implications of these findings are threefold:
- SAPT is Sufficient: For the average patient without an indication for chronic anticoagulation (e.g., atrial fibrillation, mechanical valves), single antiplatelet therapy remains the safest and most evidenced-based approach. The push to use DOACs to treat "imaging-only" findings like HALT is not supported by current clinical data.
- Focus on Procedural Excellence: If the goal is to prevent leaflet thrombosis, the solution lies in the procedural room rather than the pharmacy. Precise valve placement, optimal oversizing, and ensuring the valve frame is positioned to minimize flow disturbances are more effective strategies than systemic anticoagulation.
- Individualization vs. Routine: While the trials suggest that "routine" use is unnecessary, there may still be a niche for personalized medicine. However, such decisions should be made based on high-risk patient profiles rather than as a standard post-procedural protocol for all TAVR recipients.
Conclusion
The ACASA-TAVI and NOTION-4 trials represent the latest chapters in a long-standing effort to improve TAVR durability. While they confirm that DOACs possess the biological activity to alter the appearance of valve leaflets on a CT scan, they also serve as a reminder that radiographic findings do not always equate to clinical quality of life or improved survival.
As clinicians look toward the future, the message is clear: the most effective way to ensure the long-term success of a TAVR procedure is through the meticulous execution of the intervention itself, while adhering to conservative, evidence-based antithrombotic regimens that prioritize patient safety and minimize bleeding risks. The era of searching for a "magic bullet" to prevent subclinical thrombosis via systemic anticoagulation appears to be drawing to a close, replaced by a more nuanced, patient-centered approach.
